1,190
Views
15
CrossRef citations to date
0
Altmetric
Original Articles

Ketamine-facilitated behavioral treatment for cannabis use disorder: A proof of concept study

, , ORCID Icon, , &
Pages 92-97 | Received 08 May 2020, Accepted 08 Aug 2020, Published online: 11 Nov 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Sandra J Drozdz, Akash Goel, Matthew W McGarr, Joel Katz, Paul Ritvo, Gabriella F Mattina, Venkat Bhat, Calvin Diep & Karim S Ladha. (2022) Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature. Journal of Pain Research 15, pages 1691-1706.
Read now

Articles from other publishers (14)

Lewis Leone, Bryan McSpadden, Annamarie DeMarco, Lauren Enten, Rachel Kline & Gregory A. Fonzo. (2024) Psychedelics and Evidence-based Psychotherapy. Psychiatric Clinics of North America.
Crossref
Jenessa N. Johnston, Bashkim Kadriu, Christoph Kraus, Ioline D. Henter & Carlos A. ZarateJrJr. (2023) Ketamine in neuropsychiatric disorders: an update. Neuropsychopharmacology 49:1, pages 23-40.
Crossref
Nicholas Hovda, Winslow Gerrish, William Frizzell & Ryan Shackelford. (2024) A systematic review of the incidence of medical serious adverse events in sub-anesthetic ketamine treatment of psychiatric disorders. Journal of Affective Disorders 345, pages 262-271.
Crossref
Jeffrey William Grimm, Frances Sauter, Derek MacDougall, Emily Spaulding, Kyra Stensgaard, Mason Hardy, Kyle Griffin & Rebecca Marx. (2023) The mGlu2/3 agonist LY379268 reduces sucrose taking, seeking, and motivation in male and female rats. Behavioural Pharmacology 34:6, pages 340-349.
Crossref
Joost J. Breeksema, Alistair Niemeijer, Bouwe Kuin, Jolien Veraart, Eric Vermetten, Jeanine Kamphuis, Wim van den Brink & Robert Schoevers. (2023) Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study. Psychopharmacology 240:7, pages 1547-1560.
Crossref
Angela N. Phan & Garth E. Terry. (2023) Systematic review and rationale of using psychedelics in the treatment of cannabis use disorder. Frontiers in Psychiatry 14.
Crossref
Bess M. Kew, Richard J. Porter, Katie M. Douglas, Paul Glue, Charlotte L. Mentzel & Ben Beaglehole. (2023) Ketamine and psychotherapy for the treatment of psychiatric disorders: systematic review. BJPsych Open 9:3.
Crossref
John W. DoughertyIIIIII & David Baron. (2022) Substance Use and Addiction in Athletes: The Case for Neuromodulation and Beyond. International Journal of Environmental Research and Public Health 19:23, pages 16082.
Crossref
Mani Yavi, Holim Lee, Ioline D. Henter, Lawrence T. Park & Carlos A. ZarateJrJr. (2022) Ketamine treatment for depression: a review. Discover Mental Health 2:1.
Crossref
Mikhail L. Zobin. (2022) Some theoretical models of addictive disorder are used for behavioral transformation. Neurology Bulletin LIV:3, pages 51-61.
Crossref
Fúlvio Rieli Mendes, Cristiane dos Santos Costa, Victor Distefano Wiltenburg, Gabriela Morales-Lima, João Ariel Bonar Fernandes & Renato Filev. (2022) Classic and non‐classic psychedelics for substance use disorder: A review of their historic, past and current research. Addiction Neuroscience 3, pages 100025.
Crossref
Snehal R. Bhatt, Maya Armstrong, Tassy Parker, Marcello Maviglia, Rebecca Kass, Lawrence Leeman, Paul Romo & Douglas Ziedonis. (2022) Psychedelic Therapies at the Crossroads of Trauma and Substance Use: Historical Perspectives and Future Directions, Taking a Lead From New Mexico. Frontiers in Pharmacology 13.
Crossref
David S. Mathai, Victoria Mora & Albert Garcia-Romeu. (2022) Toward Synergies of Ketamine and Psychotherapy. Frontiers in Psychology 13.
Crossref
Samuel Kohtala. (2021) Ketamine—50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms. Pharmacological Reports 73:2, pages 323-345.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.